(Q37839231)

24 August 2017

1 reference

title

Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity (English)

1 reference

24 August 2017

1 reference

M L Avent

1

1 reference

24 August 2017

B A Rogers

series ordinal

2

1 reference

24 August 2017

A C Cheng

series ordinal

3

1 reference

24 August 2017

D L Paterson

series ordinal

4

1 reference

24 August 2017

publication date

1 June 2011

1 reference

Internal Medicine Journal

24 August 2017

published in

1 reference

24 August 2017

volume

41

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

441-449

1 reference

Pharmacodynamics and dosing of aminoglycosides

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Risk factors for toxicity in elderly patients given aminoglycosides once daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Aminoglycoside induced ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Whispered voice test for screening for hearing impairment in adults and children: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Molecular understanding of aminoglycoside action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Synthesis and spectrum of the neoglycoside ACHN-490

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

What is the evidence for once-daily aminoglycoside therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Single or multiple daily doses of aminoglycosides: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Once versus thrice daily gentamicin in patients with serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Evaluation of four once-daily aminoglycoside dosing nomograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Kinetic model for gentamicin dosing with the use of individual patient parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

A Bayesian approach to tracking patients having changing pharmacokinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02452.X

10.1111/J.1445-5994.2011.02452.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference